Access hsTnI (High Sensitivity Troponin I) Assay

Confidently report accurate results with the first true high-sensitivity troponin I assay cleared by the FDA

Access hsTnI is a true high-sensitivity troponin assay that demonstrates <10% CV at the upper reference limits (URL) for men and women and detects troponin in >50% of the healthy population. In an independent study, the assay detected troponin in >99% of healthy men and women.1 Access hsTnI provides reliable test results that your physicians can count on to make faster and more confident decisions about patient management.

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Benefits of the Access hsTnI High-sensitivity Troponin I Assay

  • Delivers quality results with a new robust design to minimize the effects of pre-analytical variability and known interferences
  • Demonstrates optimal precision at concentrations ~10x lower than previous generations of assays
  • Enables easier interpretation of test results by using whole-number reporting 
  • Increases testing flexibility as the only high-sensitivity assay to use either plasma or serum samples
  • Accurately identifies ≥94% of true acute myocardial infarction (AMI) patients in as little as one hour after presentation
  • Enables more accurate identification of women with AMI by providing separate sex-specific upper reference limits
  • Provides >99% confidence in ruling out AMI when a patient’s troponin result is below the URL

Brochure Access hsTnI Scientific Literature

Review the latest peer-reviewed analytical and clinical evaluations highlighting the value Access hsTnI can bring to your patients. 


Article The Advantages of High-sensitivity Troponin Tests

High-sensitivity troponin assays detect circulating troponin at lower levels and provide improved diagnostic clarity. Find out how these tests support accelerated decision making and improved care for patients with suspected acute coronary syndrome.

Read more
1Pretorius, C.J., et. al. “A critical evaluation of the Beckman Coulter Access hsTnI: Analytical performance, reference interval and concordance.” Clinical Biochemistry, vol. 55, 2018 May, pp. 49–55. Accessed 22 June 2018.